Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases Turpie AGArterioscler Thromb Vasc Biol 2007[Jun]; 27 (6): 1238-47Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing anticoagulants are effective, their use is limited by parenteral administration or the requirement for frequent monitoring and subsequent dose adjustment. Therefore, there is an urgent need for novel, oral agents with a predictable anticoagulant action. Because of its key position in the coagulation cascade and its limited roles outside of coagulation, Factor Xa has emerged as an attractive target for novel anticoagulants. As a result, the past decade has witnessed an explosion of research into small-molecule, oral, direct Factor Xa inhibitors, and several are now in clinical development. Rivaroxaban, LY517717, YM150, apixaban, PRT054021, and DU-176b, among others, have shown considerable promise; rivaroxaban is currently furthest ahead in its developmental program, having entered phase III in 3 indications. It is hoped that, before long, these anticoagulants will allow us to enter an era of convenient, oral anticoagulation, without the need for regular monitoring or dose adjustment.|*Factor Xa Inhibitors[MESH]|Administration, Oral[MESH]|Animals[MESH]|Anticoagulants/administration & dosage/pharmacology/*therapeutic use[MESH]|Blood Coagulation/*drug effects[MESH]|Drugs, Investigational/administration & dosage/pharmacology/*therapeutic use[MESH]|Factor Xa/metabolism[MESH]|Glycine/analogs & derivatives/therapeutic use[MESH]|Humans[MESH]|Morpholines/therapeutic use[MESH]|Piperazines/therapeutic use[MESH]|Rivaroxaban[MESH]|Thiophenes/therapeutic use[MESH]|Thromboembolism/blood/*drug therapy/prevention & control[MESH]|Treatment Outcome[MESH] |
